Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $2.95 and traded as low as $2.72. Galmed Pharmaceuticals shares last traded at $2.73, with a volume of 28,487 shares changing hands.
Separately, Zacks Investment Research cut Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 6th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Galmed Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $16.56.
The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.37 and a current ratio of 7.37. The business has a 50-day simple moving average of $2.95 and a two-hundred day simple moving average of $2.96. The company has a market capitalization of $68.48 million, a price-to-earnings ratio of -1.81 and a beta of 2.22.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Brave Asset Management Inc. acquired a new stake in shares of Galmed Pharmaceuticals in the 2nd quarter valued at approximately $35,000. Morgan Stanley lifted its holdings in shares of Galmed Pharmaceuticals by 14.3% in the 1st quarter. Morgan Stanley now owns 185,552 shares of the biopharmaceutical company’s stock valued at $636,000 after buying an additional 23,200 shares during the period. Goldman Sachs Group Inc. acquired a new stake in shares of Galmed Pharmaceuticals in the 1st quarter valued at approximately $91,000. Finally, Squarepoint Ops LLC lifted its holdings in shares of Galmed Pharmaceuticals by 161.2% in the 1st quarter. Squarepoint Ops LLC now owns 54,884 shares of the biopharmaceutical company’s stock valued at $188,000 after buying an additional 33,874 shares during the period. 19.19% of the stock is owned by institutional investors and hedge funds.
About Galmed Pharmaceuticals (NASDAQ:GLMD)
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.
Featured Article: S&P 500 Index
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.